UNIVERSAL IBOGAINE INC. Financials Universal Ibogaine Inc. Toronto S.E.
Equities
IBO
CA69379R1082
Healthcare Facilities & Services
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.01 CAD | -33.33% |
|
-33.33% | +100.00% |
| Apr. 22 | Universal Ibogaine Inc. announced that it expects to receive CAD 0.35 million in funding | CI |
| Apr. 12 | Universal Ibogaine Inc. announced that it expects to receive CAD 0.6 million in funding | CI |
Valuation
| Fiscal Period: July | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 7.63 | 2.872 |
| Enterprise Value (EV) 1 | 8.641 | 5.336 |
| P/E ratio | -0.67 x | -1.2 x |
| Yield | - | - |
| Capitalization / Revenue | 7,125,247 x | 2,788,771 x |
| EV / Revenue | 8,069,982 x | 5,181,017 x |
| EV / EBITDA | -1.93 x | -3.04 x |
| EV / FCF | -5,892,239 x | -6,580,841 x |
| FCF Yield | -0% | -0% |
| Price to Book | 1.94 x | 1.64 x |
| Nbr of stocks (in thousands) | 190,744 | 191,494 |
| Reference price 2 | 0.0400 | 0.0150 |
| Announcement Date | 11/30/22 | 1/26/24 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: July | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales | - | - | - | 1.071 | 1.03 |
| EBITDA 1 | -1.296 | -2.362 | -3.795 | -4.48 | -1.755 |
| EBIT 1 | -1.724 | -3.366 | -3.865 | -4.746 | -2.051 |
| Operating Margin | - | - | - | -443.24% | -199.1% |
| Earnings before Tax (EBT) 1 | -2.459 | -5.571 | -3.867 | -10.5 | -2.39 |
| Net income 1 | -2.459 | -5.571 | -3.867 | -10.5 | -2.39 |
| Net margin | - | - | - | -980.22% | -232.08% |
| EPS 2 | -0.1300 | -0.1625 | -0.0309 | -0.0600 | -0.0125 |
| Free Cash Flow | - | -1.379 | -1.713 | -1.467 | -0.8109 |
| FCF margin | - | - | - | -136.96% | -78.73% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 8/30/21 | 8/30/21 | 11/29/21 | 11/30/22 | 1/26/24 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: July | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt 1 | 0.58 | 0.46 | 0.27 | 1.01 | 2.46 |
| Net Cash position 1 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -0.4495 x | -0.1957 x | -0.0706 x | -0.2258 x | -1.404 x |
| Free Cash Flow | - | -1.38 | -1.71 | -1.47 | -0.81 |
| ROE (net income / shareholders' equity) | - | -638% | -316% | -305% | -84% |
| ROA (Net income/ Total Assets) | - | -108% | -106% | -57.5% | -21.7% |
| Assets 1 | - | 5.147 | 3.638 | 18.24 | 11.02 |
| Book Value Per Share 2 | 0.1200 | -0.0100 | 0.0200 | 0.0200 | 0.0100 |
| Cash Flow per Share 2 | 0 | 0 | 0 | 0 | 0 |
| Capex 1 | 0.36 | - | - | 0.1 | 0.36 |
| Capex / Sales | - | - | - | 8.94% | 34.96% |
| Announcement Date | 8/30/21 | 8/30/21 | 11/29/21 | 11/30/22 | 1/26/24 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -14.92% | 84.68B | |
| +13.30% | 81.12B | |
| +11.62% | 29.4B | |
| -12.71% | 16.73B | |
| -3.06% | 16.36B | |
| -2.63% | 14.92B | |
| -31.75% | 11.77B | |
| -1.42% | 11.72B | |
| +27.44% | 11.71B |
- Stock Market
- Equities
- IBO Stock
- IBO Stock
- Financials Universal Ibogaine Inc.
